Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated influenza vaccine + FB-631
- Development stage
- Unknown
- Lead developer
- Folia Biotech
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent inactivated influenza vaccine + FB-631 is a combination vaccine consisting of a standard seasonal trivalent inactivated influenza vaccine (TIV) and Folia Biotech's proprietary PAL adjuvant (FB-631). The FB-631 adjuvant is composed of nanoparticles formed from the recombinant coat protein of the papaya mosaic virus (PapMV). This plant virus-derived platform is designed to enhance the immune response to the influenza antigens by stimulating both humoral and cellular immunity. In clinical evaluation, the 2013-2014 formulation of Fluviral was used as the base TIV. The vaccine was developed by Folia Biotech Inc. to provide improved protection against seasonal influenza, particularly in populations with weakened immune responses.
- Other names
- PAL adjuvant co-administered with seasonal TIVPapMV-adjuvanted TIV
02
Targets
HA (Hemagglutinin)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on trivalent inactivated influenza vaccine + FB-631.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated influenza vaccine + FB-631.